Literature DB >> 2649174

Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts.

C A Keever1, T N Small, N Flomenberg, G Heller, K Pekle, P Black, A Pecora, A Gillio, N A Kernan, R J O'Reilly.   

Abstract

The reconstitution of hematopoietic cells and in vitro assays of immunologic function have been followed in leukemic patients after conventional bone marrow transplantation (BMT) (N = 34) and T-cell depleted BMT (N = 52) from human leukocyte antigen (HLA)-identical sibling donors. No effects of the T-cell depletion could be seen on the recovery of myeloid or lymphoid cells as measured by the day to engraftment or by the absolute number of cells through day 100. Normal numbers of lytically active natural killer cells returned the earliest and were rapidly followed in both groups of patients by the appearance of circulating B cells and normalization of the responses to B-cell mitogens. However, the recovery of normal T-cell proliferative responses were more delayed in recipients of T-cell depleted grafts. Significant quantitative differences were seen only during the first 3 months after transplantation. Neither the number of CD3+ T cells nor the ratio of CD4:CD8 positive cells differed markedly between the two transplant groups. Mitogen-induced immunoglobulin production by peripheral blood lymphocytes (PBL) from patients following T-cell depleted BMT was quantitatively less than that of conventional marrow recipients through the first year, with low normal IgM production reached by 4 to 6 months in both groups. IgG production reached low normal 7 to 9 months after conventional BMT but did not remain at this level until 1 year following either type of transplant. Assessment of the incidence of infections from the day the absolute neutrophil count reached 500 until day 180 after transplant revealed no significant differences between the two groups; indeed, the overall nonleukemic mortality was higher in the recipients of conventional bone marrow. Thus, in our series, the removal of mature cells from the marrow graft did not affect the rate or degree of recovery of myeloid and lymphoid cells but did affect the regeneration of in vitro T-cell dependent functions. We noted early quantitative differences and a delay in the normalization of the T-cell functions measured rather than prolonged absolute deficiencies. The in vitro deficiencies did not result in significant clinically apparent differences between the two groups.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649174

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

Review 1.  Hematopoietic stem cell transplantation for severe combined immune deficiency.

Authors:  K I Weinberg; N Kapoor; A J Shah; G M Crooks; D B Kohn; R Parkman
Journal:  Curr Allergy Asthma Rep       Date:  2001-09       Impact factor: 4.806

Review 2.  Post-transplant immune recovery and the implication for infection risk.

Authors:  Michael E Trigg
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 3.  Management of graft-versus-host disease in paediatric bone marrow transplant recipients.

Authors:  M Zecca; F Locatelli
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

4.  Haploidentical hematopoietic stem cell transplantation for nonresponders to immunosuppressive therapy against acquired severe aplastic anemia.

Authors:  L Liu; X Wang; S Jin; L Hao; Y Zhang; X Zhang; D Wu
Journal:  Bone Marrow Transplant       Date:  2015-10-19       Impact factor: 5.483

5.  Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: functional analyses of lymphocytes and correlation with immunophenotypic recovery following transplantation.

Authors:  H Kook; F Goldman; R Giller; N Goeken; C Peters; M Comito; S Rumelhart; M Holida; N Lee; M Trigg
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

6.  Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation.

Authors:  Antonia M S Müller; Jessica A Linderman; Mareike Florek; David Miklos; Judith A Shizuru
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

7.  CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.

Authors:  Roni Tamari; Stephen S Chung; Esperanza B Papadopoulos; Ann A Jakubowski; Patrick Hilden; Sean M Devlin; Jenna D Goldberg; Miguel-Angel Perales; Doris M Ponce; Craig S Sauter; Molly A Maloy; Dara Y Herman; Virginia Klimek; James W Young; Richard J O'Reilly; Sergio A Giralt; Hugo Castro-Malaspina
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-14       Impact factor: 5.742

8.  Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.

Authors:  Marie Bleakley; Shelly Heimfeld; Lori A Jones; Cameron Turtle; Diane Krause; Stanley R Riddell; Warren Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-11       Impact factor: 5.742

Review 9.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

10.  Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity.

Authors:  Jeffrey K Davies; Dongin Yuk; Lee M Nadler; Eva C Guinan
Journal:  Transplantation       Date:  2008-09-27       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.